COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib
COMPEL 研究：奥希替尼联合铂类化疗治疗一线奥希替尼治疗后进展的 EGFR 突变晚期非小细胞肺癌患者
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105807
Peled, N; Tufman, A; Sequist, L V; Pasello, G; Wang, Q; Antonuzzo, L; González Larriba, J; Medina Valdivieso, S; Cobo Dols, M; Milella, M; Dudnik, J; Martín-Martorell, P; Barneto Aranda, I; Huang, D; Palicio, N V; Scimone, A; Bria, E; Servidio, L; Pimentel, R; Ganiyu, A-A; Zhao, J
肺癌
肿瘤
肿瘤免疫
EGF
OMP
COMP
EGFR
细胞生物学
